Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Joshua Knapp, Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6398.

https://doi.org/10.1182/blood-2025-6398

Published: 2025

Journal Articles

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Blood (2025) 146 (Supplement 1): 768.

https://doi.org/10.1182/blood-2025-768

Published: 2025

Journal Articles

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Razan Mohty, Kendall Diebold, Todd Mudd, Maris Hardee, Jay Jarodiya, Katherine Parks, Kimo Bachiashvili, Manuel Espinoza-Gutarra, Sravanti Rangaraju, Pankit Vachhani, Omer Jamy

Blood (2025) 146 (Supplement 1): 5272.

https://doi.org/10.1182/blood-2025-5272

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Todd Mudd, Kendall Diebold, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 5220.

https://doi.org/10.1182/blood-2025-5220

Published: 2025

Journal Articles

Evolving use of blast percentage thresholds and classification systems in AML clinical trials (2022–2025): A data-driven trend analysis

Tiantian Zhang, John Choi, Kimo Bachiashvili

Blood (2025) 146 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2025-1631

Published: 2025

Journal Articles

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

Benjamin McCormick, Omer Jamy, Manuel Espinoza-Gutarra, Ravi Bhatia, Kimo Bachiashvili, Sravanti Rangaraju, Devan Parker, Sarah Worth, Pankit Vachhani, Razan Mohty

Blood (2025) 146 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2025-1668

Published: 2025

Journal Articles

Outcomes of adult T-cell acute lymphoblastic leukemia/lymphoma in a real-world cohort: A single institution experience in the deep south

Maris Hardee, Jay Jarodiya, Kimo Bachiashvili, Ravi Bhatia, Manuel Espinoza-Gutarra, Omer Jamy, Razan Mohty, Pankit Vachhani, Sravanti Rangaraju

Blood (2025) 146 (Supplement 1): 8084.

https://doi.org/10.1182/blood-2025-8084

Published: 2025

Journal Articles

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Kendall Diebold, Todd Mudd, Jay Jarodiya, Katherine Parks, Maris Hardee, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Manuel Espinoza-Gutarra, Razan Mohty, Ravi Bhatia, Omer Jamy

Blood (2024) 144 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2024-204120

Published: 2024

Journal Articles

Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)

Sravanti Rangaraju, Kendall Diebold, Pankit Vachhani, Omer Jamy, Kimo Bachiashvili, Ravi Bhatia, Razan Mohty, Manuel Espinoza-Gutarra, Joshua Oliver, Barry Diamond, Kaitlin Moulton, Zaid Al-Kadhimi

Blood (2024) 144 (Supplement 1): 2808.

https://doi.org/10.1182/blood-2024-211985

Published: 2024

Journal Articles

TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Blood (2024) 144 (Supplement 1): 878.

https://doi.org/10.1182/blood-2024-201101

Published: 2024

Journal Articles

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Greg Bascug, Garrett Bourne, Kendall Diebold, Joshua Knapp, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 7425.

https://doi.org/10.1182/blood-2023-184757

Published: 2023

Journal Articles

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Kendall Diebold, Sarah Worth, Kimo Bachiashvili, Pankit Vachhani, Sravanti Rangaraju, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5910.

https://doi.org/10.1182/blood-2023-185198

Published: 2023

Journal Articles

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2023-189853

Published: 2023

Journal Articles

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Kimo Bachiashvili, Shuko Harada, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Vivek Chopra, Cat N. Bui, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2023-179370

Published: 2023

Journal Articles

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Kimo Bachiashvili, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Cat N. Bui, Sarah Worth, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 7415.

https://doi.org/10.1182/blood-2023-178008

Published: 2023

Journal Articles

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Blood (2023) 142 (Supplement 1): 318.

https://doi.org/10.1182/blood-2023-179131

Published: 2023

Journal Articles

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

Omer H Jamy, Kendall Diebold, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Kelly N. Godby, Donna Salzman, Ravi Bhatia

Blood (2022) 140 (Supplement 1): 8959–8960.

https://doi.org/10.1182/blood-2022-160346

Published: 2022

Journal Articles

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Guillermo Garcia-Manero, Kimo Bachiashvili, Harshad Amin, Elie Traer, Daniel A. Pollyea, David A. Sallman, Aref Al-Kali, Larry D. Cripe, Jesus G Berdeja, Elizabeth A. Griffiths, Sanjay R Mohan, Yuri Sano, Aram Oganesian, Harold N. Keer, Abdulraheem Yacoub

Blood (2022) 140 (Supplement 1): 1112–1114.

https://doi.org/10.1182/blood-2022-156512

Published: 2022

Journal Articles

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Omer Hassan Jamy, Sarah Worth, Sravanti Rangaraju, Kimo Bachiashvili, Pankit Vachhani, Ravi Bhatia

Blood (2021) 138 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2021-149778

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia

Evolving use of blast percentage thresholds and classification systems in AML clinical trials (2022–2025): A data-driven trend analysis

Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

Outcomes of adult T-cell acute lymphoblastic leukemia/lymphoma in a real-world cohort: A single institution experience in the deep south

Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)

TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53 -Mutated Acute Myeloid Leukemia

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only